• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
    • Just look at what our Tens of Thousands of Satisfied Customers say about us
    Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Sun Pharma > March 14, 2012

      Sun Pharma Advanced Research Company Announces Rights Issue to Conduct Clinical Trial of Paclitaxel in US

      Sun Pharma Advanced Research Company (SPARC), an India-based publicly listed pharma research company, has announced that it will issue additional shares to fund its clinical trials to be conducted in the US. SPARC plans to raise gross proceeds of up to $44.6 million from this rights issue to its existing shareholders. The company will utilize the raised funds to conduct the first phase of tests to study the safety and efficacy of Paclitaxel, a new form of cancer injection, in the US. Also, it intends to use a significant amount of the funds to repay its debts.

      Paclitaxel is a cancer chemotherapy drug that is licensed to treat advanced stage of cancer of the ovary, breast and lung. SPARC aims to develop and test a new patient-friendly administration protocol for Paclitaxel, namely a Paclitaxel Injection Concentrate for Nano dispersion (PICN) that is safer, with a short infusion time and high-dose drug delivery to tumor tissues.

       

      Share this Article!

    Back to top^